GeneHealth - Your precision medicine

D-bifunctional Protein Deficiency

Disease Details

Family Health Simplified

Buy Membership

Description: D-bifunctional protein deficiency is a rare autosomal recessive disorder characterized by severe neurological impairment and developmental regression due to defects in peroxisomal beta-oxidation of fatty acids.
Type: D-bifunctional protein deficiency is a genetic disorder transmitted in an autosomal recessive pattern.
Signs And Symptoms: D-bifunctional protein deficiency is a rare and severe metabolic disorder.

**Signs and Symptoms:**
- Developmental delay or regression
- Hypotonia (reduced muscle tone)
- Seizures
- Feeding difficulties
- Hearing and vision problems
- Liver dysfunction

Symptoms usually appear in newborns or early infancy and can lead to severe, life-threatening complications.
Prognosis: D-bifunctional protein deficiency (DBPD) is a severe and typically fatal peroxisomal disorder that affects the breakdown of certain fatty acids and the synthesis of plasmalogens. The prognosis for individuals with DBPD is generally poor. Most infants present with severe neurological symptoms and developmental delays shortly after birth. Life expectancy is significantly reduced, with many affected individuals not surviving beyond the first few years of life. There is currently no cure for DBPD, and treatment focuses on managing symptoms and supportive care.
Onset: D-bifunctional protein deficiency typically has an onset in the neonatal period or early infancy.
Prevalence: There is no widely available data on the exact prevalence of d-bifunctional protein deficiency, but it is considered to be a very rare disorder.
Epidemiology: D-Bifunctional protein deficiency (DBPD) is a rare autosomal recessive disorder affecting the peroxisomal beta-oxidation of very long-chain fatty acids. It primarily impacts newborns and infants, often leading to severe neurological abnormalities and developmental delays. Epidemiological data is limited due to the rarity of the condition, but it is estimated to occur in approximately 1 in 100,000 to 1 in 500,000 live births. The disorder does not show a clear ethnic or geographical predilection.

If needed, I can provide more detailed information on clinical features, diagnosis, or management of the disorder.
Intractability: D-Bifunctional protein deficiency is considered an intractable disease because there is currently no cure. It is a rare, severe, inherited metabolic disorder that affects the body's ability to break down certain fats. Management focuses on supportive care and symptomatic treatment.
Disease Severity: D-bifunctional protein deficiency is a severe genetic disorder that primarily affects the nervous system. Patients with this condition typically present with profound neurological impairments, including developmental delay, hypotonia, seizures, and other serious symptoms. The prognosis is generally poor, with many affected individuals not surviving beyond early childhood.
Healthcare Professionals: Disease Ontology ID - DOID:0090031
Pathophysiology: D-Bifunctional protein deficiency is a rare, inherited metabolic disorder affecting the peroxisomal beta-oxidation of fatty acids. It is caused by mutations in the HSD17B4 gene, which encodes the D-bifunctional protein (DBP). This protein has two key enzyme activities: enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase, both essential for the degradation of very long-chain fatty acids, branched-chain fatty acids, and bile acid intermediates.

In individuals with this deficiency, the defective or missing DBP leads to the accumulation of unmetabolized fatty acids and their derivatives. This accumulation disrupts normal cellular functions, particularly in the central nervous system, liver, and kidneys, leading to a range of severe symptoms including developmental delay, hypotonia, seizures, and organ dysfunction.
Carrier Status: Carrier status for D-bifunctional protein deficiency refers to individuals who have one copy of the mutated gene responsible for the disorder, often without exhibiting symptoms. They can pass the mutated gene to their offspring, who may be at risk if they inherit another mutated copy from the other parent. This disorder follows an autosomal recessive inheritance pattern.
Mechanism: D-bifunctional protein deficiency is a rare, inherited metabolic disorder that affects the peroxisomal biochemical pathways. The condition is caused by mutations in the HSD17B4 gene, which encodes the D-bifunctional protein (DBP). This multifunctional enzyme is critical for the β-oxidation of very long-chain fatty acids and other substrates within peroxisomes.

Mechanism:
In individuals with D-bifunctional protein deficiency, mutations in the HSD17B4 gene lead to a defective or non-functional DBP. As a result, peroxisomes cannot effectively metabolize very long-chain fatty acids, leading to their accumulation in various tissues. This accumulation disrupts normal cellular functions and contributes to the severe developmental and neurological symptoms observed in affected individuals.

Molecular Mechanisms:
1. Enzyme Dysfunction: HSD17B4 gene mutations result in the production of an abnormal DBP protein, which may be unstable, misfolded, or have reduced enzymatic activity. This directly impairs the β-oxidation of fatty acids.
2. Metabolite Accumulation: Due to ineffective peroxisomal β-oxidation, very long-chain fatty acids and other toxic intermediates accumulate, causing cellular damage and contributing to disease pathology.
3. Neural and Systemic Impact: The buildup of unmetabolized lipids can interfere with normal neuronal function, leading to developmental delays, seizures, hypotonia, and other neurological issues. Additionally, other organs may be affected, contributing to a multi-systemic disorder.

D-bifunctional protein deficiency generally presents early in life with severe symptoms and is often fatal within the first few years. Current treatments are mostly supportive, focusing on managing symptoms and improving quality of life.
Treatment: D-bifunctional protein deficiency is a rare genetic disorder that affects the body's ability to break down very-long-chain fatty acids, leading to severe neurological and other systemic symptoms. Currently, there is no cure for this condition. Treatment primarily focuses on managing symptoms and providing supportive care. This may include:

1. Specialized diets to manage metabolic imbalances.
2. Seizure control through the use of antiepileptic medications.
3. Physical, occupational, and speech therapy to support development.
4. Management of feeding difficulties, potentially involving a feeding tube.

Supportive care is tailored to the individual's symptoms and may involve a multidisciplinary team of healthcare providers.
Compassionate Use Treatment: D-bifunctional protein deficiency (DBPD) is a rare, inherited metabolic disorder affecting the breakdown of fatty acids in the body. Currently, there are no specific approved treatments for this condition. However, various options have been explored under compassionate use or as experimental treatments:

1. **Compassionate Use Treatment:**
- **Dietary Management:** Special diets, such as those low in very-long-chain fatty acids (VLCFA), as well as the supplementation of medium-chain triglycerides (MCTs), may help manage some symptoms.
- **Supportive Care:** Providing supportive treatments to manage symptoms and maintain patient comfort is often the core approach under compassionate use. This could involve physical therapy, occupational therapy, and management of seizures.

2. **Off-label or Experimental Treatments:**
- **Cholic Acid Therapy:** While primarily used for bile acid synthesis disorders, cholic acid has been considered in some experimental settings to help manage symptoms of DBPD.
- **Gene Therapy and Enzyme Replacement Therapy:** These are hypothetical and experimental interventions that aim to address the underlying genetic defects but, as of now, are still in the research phases and not available for clinical use.
- **Pharmacological Approaches:** Trials with antioxidants, anti-inflammatory drugs, or agents that modulate the peroxisome proliferator-activated receptor (PPAR) pathways are considered experimental approaches aimed at mitigating secondary effects.

Overall, management of DBPD remains largely supportive and symptomatic, with experimental therapies being an area of ongoing research.
Lifestyle Recommendations: D-bifunctional protein deficiency is a rare, autosomal recessive metabolic disorder. Lifestyle recommendations for individuals with this condition typically include supportive and symptomatic care rather than specific lifestyle adjustments due to the severity and complexity of the disease. It's crucial to work closely with a team of healthcare providers, including metabolic specialists, neurologists, and dietitians, to manage symptoms and improve quality of life.

Given the profound impact on multiple systems, the primary focus is on managing symptoms and ensuring patient comfort. Regular medical follow-ups, early intervention programs, and supportive therapies (such as physical, occupational, and speech therapy) are typically recommended. Genetic counseling may also be beneficial for families.

Specific lifestyle changes can be difficult to recommend without a tailored management plan, as the severity and symptoms can vary widely. However, maintaining a safe, stress-free environment and ensuring good nutritional support appropriate for the individual's needs are generally advised.
Medication: There is currently no specific medication for d-bifunctional protein deficiency. The treatment primarily focuses on managing symptoms and providing supportive care, such as specialized dietary plans and physical therapy, to improve the quality of life for affected individuals. Regular monitoring and a multidisciplinary approach involving various healthcare professionals are essential for managing the condition.
Repurposable Drugs: D-Bifunctional protein deficiency (DBPD) is a severe disorder affecting the peroxisomal beta-oxidation of very-long-chain fatty acids. Currently, there are limited treatment options, and research into repurposing existing drugs is ongoing. Some potential repurposable drugs under investigation for related metabolic disorders, though not specifically confirmed for DBPD, include bezafibrate and resveratrol. However, more research is needed to ascertain their efficacy and safety for DBPD patients. Consulting with a specialist is crucial for up-to-date and personalized medical advice.
Metabolites: D-Bifunctional Protein Deficiency (DBPD) is a rare genetic disorder affecting peroxisomal fatty acid oxidation. Metabolites often found at elevated levels in patients include very-long-chain fatty acids (VLCFAs), branched-chain fatty acids (such as pristanic acid), bile acid intermediates, and phytanic acid. The accumulation of these metabolites can be used to help diagnose the condition.
Nutraceuticals: D-Bifunctional protein deficiency is a rare genetic disorder that affects the breakdown of certain fatty acids in the body. Nutraceuticals (a term combining "nutrition" and "pharmaceuticals") have not been proven to effectively treat or manage this condition. Management typically focuses on supportive care and addressing the symptoms. Always consult healthcare professionals for guidance on treatment and management options.
Peptides: For D-bifunctional protein deficiency (DBPD), the term "peptides" typically refers to the short chains of amino acids involved in various biochemical processes. Specifically, the condition is related to the metabolism of peroxisome-produced lipids, where impaired enzyme function affects peptide synthesis and breakdown related to fatty acid oxidation.

Regarding "nan," if this refers to nanoscale interventions or nanoparticles, currently, there is no standard treatment involving nanotechnology for DBPD. The disease is managed through supportive care, symptomatic treatment, and dietary modifications, but no nanotherapeutics are widely accepted or practiced for this condition as of now.